Kura Oncology, Inc. (FRA:KUR)

Kura Oncology Statistics

Total Valuation

Kura Oncology has a market cap or net worth of EUR 911.03 million. The enterprise value is 453.79 million.

Market Cap	911.03M
Enterprise Value	453.79M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	87.02M
Shares Outstanding	n/a
Shares Change (YoY)	+4.45%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	1.54%
Owned by Institutions (%)	74.05%
Float	64.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	10.28
PB Ratio	4.41
P/TBV Ratio	4.41
P/FCF Ratio	12.86
P/OCF Ratio	12.17
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.45
EV / Sales	5.06
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	6.41

Financial Position

The company has a current ratio of 5.12, with a Debt / Equity ratio of 0.08.

Current Ratio	5.12
Quick Ratio	4.83
Debt / Equity	0.08
Debt / EBITDA	n/a
Debt / FCF	0.23
Interest Coverage	-152.85

Financial Efficiency

Return on equity (ROE) is -65.10% and return on invested capital (ROIC) is -42.68%.

Return on Equity (ROE)	-65.10%
Return on Assets (ROA)	-26.57%
Return on Invested Capital (ROIC)	-42.68%
Return on Capital Employed (ROCE)	-45.41%
Revenue Per Employee	461,791
Profits Per Employee	-962,762
Employee Count	192
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

In the past 12 months, Kura Oncology has paid 1.91 million in taxes.

Income Tax	1.91M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -3.45% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-3.45%
50-Day Moving Average	8.65
200-Day Moving Average	6.56
Relative Strength Index (RSI)	58.61
Average Volume (20 Days)	198

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.53

Income Statement

In the last 12 months, Kura Oncology had revenue of EUR 88.66 million and -184.85 million in losses. Loss per share was -2.11.

Revenue	88.66M
Gross Profit	-42.06M
Operating Income	-204.40M
Pretax Income	-182.94M
Net Income	-184.85M
EBITDA	-203.69M
EBIT	-204.40M
Loss Per Share	-2.11

Balance Sheet

The company has 468.48 million in cash and 16.59 million in debt, giving a net cash position of 451.89 million.

Cash & Cash Equivalents	468.48M
Total Debt	16.59M
Net Cash	451.89M
Net Cash Per Share	n/a
Equity (Book Value)	206.72M
Book Value Per Share	2.38
Working Capital	425.60M

Cash Flow

In the last 12 months, operating cash flow was 74.83 million and capital expenditures -4.00 million, giving a free cash flow of 70.84 million.

Operating Cash Flow	74.83M
Capital Expenditures	-4.00M
Free Cash Flow	70.84M
FCF Per Share	n/a

Margins

Gross margin is -47.44%, with operating and profit margins of -230.53% and -208.48%.

Gross Margin	-47.44%
Operating Margin	-230.53%
Pretax Margin	-206.33%
Profit Margin	-208.48%
EBITDA Margin	-229.73%
EBIT Margin	-230.53%
FCF Margin	79.89%

Dividends & Yields

Kura Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.45%
Shareholder Yield	-4.45%
Earnings Yield	-20.29%
FCF Yield	7.78%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Kura Oncology has an Altman Z-Score of -1.43 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.43
Piotroski F-Score	3